The industry might focus less on the detail of the outcome of the discount rate review in favour of using it to contest the prevailing mindset that dominates HTA decision-making. …
The problem in this system is that the payer will insist it is right even when it is wrong
November 23, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma -
Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant
June 19, 2025 - - Latest News -
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 - - Australian Biotech -
NZ Government expands access to melatonin and psilocybin
June 18, 2025 - - Latest News -
Imugene announces US patent allowance for onCARlytics
June 18, 2025 - - Australian Biotech